irk Deleu graduated with 'magna cum laude' from the Medical School of the University of Brussels (Vrije Universiteit Brussel) in 1983. He pursued his postgraduate residency training in Neurology at the same institution and became board certified Neurologist in 1988. Subsequently, he became permanently affiliated to the Department of Neurology at the University Hospital of Brussels  (Akademisch Ziekenhuis Vrije Universiteit Brussel)(

Very early in his medical training he became interested in neuropharmacology and neurochemistry which prompted him as a last year medical student to start at the same time his medical research, which was focused on the regional distribution of acidic dopamine metabolites in human brain. During his residency in Neurology, he became more involved in movement disorders and particularly the neuropharmacologic aspects of Parkinson's disease. He obtained several academic titles (M.Sc., Ph.D.) at his mother institution and received his Professorial degree (Aggregaatsthesis van het Hoger Onderwijs) in 1994. His thesis focused on the study of the peripheral pharmacokinetics and metabolism of levodopa using microdialysis.

He has over 100 publications covering all fields of neuroscience and is an active member of several international editorial and review boards. His contribution to neurology has resulted in his election as Fellow of the American Academy of Neurology and Fellow of the Royal College of Physicians (Edinburgh). An overview of the author's curriculum vitae can be found at CV.

From 1993, Dirk Deleu was affiliated to Sultan Qaboos University and its teaching Hospital (Sultan Qaboos University Hospital) in the Sultanate of Oman. In August 2003, he joined the Department of Neurology (Medicine) at Hamad Medical Corporation ( in Doha, State of Qatar. He is currently Senior Consultant and Head of Neurology and Neurophysiology, and Professor Clinical Neurology & Neurosciences at Weill Cornell Medical College - Qatar and has been appointed as Regional Adviser to the Royal College of Physicians of Edinburgh.

The author wishes to acknowledge Kathy & Ellen Deleu for their technical and scientific contributions in the development of the website.

Selection of publications:

    • Deleu D, Solheid C, Michotte A, et al. Dissociated ipsilateral horizontal gaze palsy in one-and-a-half syndrome: A clinicopathologic study. Neurology 1988;38:1278-1280.
    • Deleu D, Ebinger G, Michotte Y. A clinical and pharmacokinetic comparison of oral and duodenal delivery of  levodopa/carbidopa in patients with Parkinson's disease with fluctuating responses to levodopa. European Journal of Clinical Pharmacology 1991;41:453-458.
    • Sarre S, Herregodts P, Deleu D, et al. Biotransformation of L-DOPA in striatum and substantia nigra in rats with unilateral nigrostriatal lesion: a microdialysis study. Naunyn-Schmiedeberg's Archives of Pharmacology 1992;346:277-285.
    • Deleu D, Sarre S, Ebinger G, et al. The effect of carbidopa and entacapone pretreatment on the L-DOPA pharmacokinetics and metabolism in blood plasma and skeletal muscle in beagle dog: An in vivo microdialysis study. Journal of Pharmacology and Experimental Therapeutics 1995;273:1323-1331.
    • Deleu D, Hanssens Y. Loss of aura in lamotrigine-treated epilepsy. Lancet 1997;350:1751-1752.
    • Deleu D, Bamanikar S, Muirhead D, et al. Familial progressive sensorimotor neuropathy with agenesis of the corpus callosum (Andermann syndrome): a clinical, neuroradiological and histopathological study. European Neurology 1997;37:104-109.
    • Deleu D, Hanssens Y. Current and second generation triptans in acute migraine therapy: a comparative review. Journal of Clinical Pharmacology 2000;40:1-14.
    • Deleu D, Aarons L, Ahmed I. Population pharmacokinetics of free carbamazepine in adult Omani epileptic patients. European Journal of Clinical Pharmacology 2001;57:243-248.
    • Deleu D, Northway M, Hanssens Y. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease. Clinical Pharmacokinetics 2002;41:261-309.
    • Deleu D, Khan MA, Al Shehab T. Prevalence and clinical characteristics of headache in a rural community in Oman. Headache 2002;42:963-973.
    • Deleu D. Levetiracetam in the treatment of idiopathic hemifacial spasm. Neurology 2004;62:2134-2135.
    • Deleu D, Hanssens Y, Northway M. Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease. Drugs Aging 2004;21:687-709.
    • Deleu D, Aarons L, Ahmed I. Estimation of population pharmacokinetic parameters of free-phenytoin in adult epileptic patients. Archives of Medical Research 2005;36:49-53.
    • Deleu D, Hamad AA, Kamram S, et al. Ethnic variations in risk factor profile, pattern and recurrence of non-cardioembolic ischemic stroke. Archives of Medical Research 2006;37:655-662.
    • Deleu D, Jacob P, Chand P, et al. Effects of caffeine on levodopa pharmacokinetics and pharmacodynamics in Parkinson's disease. Neurology 2006;67:897-899.
    • Deleu D, Kamran S, Hamad AA, et al. Segmental ventricular wall motion abnormalities are associated with lacunar ischemic stroke. Clinical Neurology and Neurosurgery 2006;108:744-749.
    • Deleu D. Levodopa, motor complications and disease progression. Journal of Neurological Sciences 2008;273:155-69.
    • Akhtar N, Kamran S, Deleu D, et al. Pattern of ischemic posterior circulation stroke in the state of Qatar. European Journal of Neurology (in press).

Back to Top

Text Box: About the author
Text Box: Content

Text Box: Home
Text Box: Abbreviations
Text Box: Subscribe
Text Box: Educational support
Text Box: Search

Home | About the Author | Content | Abbreviations | Subscribe |Educational support| Search